Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience.
Oren LedderMichael DolingerMarla C DubinskyRonen SteinSrisindu VellankiRachel BuckukAyesha FatimaDavid L SuskindJarrad ScarlettDennis RöserDror S ShouvalGabriele MeyerZarela Molle RiosGemma Pujol-MuncunillAnna LozanoKaija-Leena KolhoPejman RohaniSéamus HusseyTim de MejjTravis AyersVictor Manuel Navas-LópezDan TurnerChristos TzivinikosPublished in: Inflammatory bowel diseases (2024)
In this largest real-life pediatric cohort to date, tofacitinib was effective in at least 16% of patients with highly refractory UC by week 8. Adverse events were minor and largely consistent with adult data.